Literature DB >> 2757956

Interferon response to dipyridamole in lupus erythematosus patients.

K Konstantinov1, A Galabov, M Mastikova.   

Abstract

Studies in patients with autoimmune disorders strongly support a role for interferon (IFN) in the disease process. In the present study we investigated the in vivo production of alpha-IFN in lupus erythematosus patients after stimulation with dipyridamole, recently characterized as an alpha-IFN inducer in mice and humans. Levels of IFN were measured in serum samples from 22 patients with systemic lupus erythematosus (SLE) and 12 patients with discoid lupus erythematosus (DLE) before and 24 h after dipyridamole administration. IFN activity was assayed on human and bovine cells in parallel. Initial serum concentrations of alpha-IFN in SLE patients were markedly elevated. The percentage of DLE positive responders to dipyridamole induction was about twice as high as that found for SLE. Studies of factors responsible for IFN production in lupus erythematosus might result in better understanding of the relationship between DLE and SLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757956     DOI: 10.1111/j.1365-2133.1989.tb01400.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Dipyridamole, as an interferon inducer, versus placebo in the prevention of recurrences of condylomata acuminata after diathermocoagulation.

Authors:  G Mancuso; M Reggiani; R M Berdondini; A Errani
Journal:  Genitourin Med       Date:  1995-02

2.  Systematic discovery of multicomponent therapeutics.

Authors:  Alexis A Borisy; Peter J Elliott; Nicole W Hurst; Margaret S Lee; Joseph Lehar; E Roydon Price; George Serbedzija; Grant R Zimmermann; Michael A Foley; Brent R Stockwell; Curtis T Keith
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

3.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.